| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Legal Officer | EVP, General Counsel
1 company
George Eric Davis is EVP, Chief Legal Officer at BMRN. From June 2016 to September 2026, the filings on record show 0 open-market purchases and 33 sales. The disclosed holdings are worth an estimated $4.0M at current prices.
Our model assigns George Eric Davis a middling insider score of 65/100, based on 13 past trades. Over a 12-month horizon, 58.3% of those trades were profitable, with an average 12-month return of +5.4%.
The BMRN filings lean toward selling, a net 345,212 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 23, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 3,350 | $81.35 | $272,522.50 | -3.7% | |
| Mar 16, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 3,818 | $83.88 | $320,253.84 | -3.9% | |
| Mar 5, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 2,105 | $79.04 | $166,379.20 | -2.3% | |
| Feb 1, 2018 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sale+OE | 30,000 | $90.66 | $2,719,665.00 | -26.6% | |
| Nov 30, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 1,200 | $85.64 | $102,766.80 | -1.4% | |
| Jun 23, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sale+OE | 9,844 | $96.60 | $950,930.40 | -10.5% | |
| Jun 5, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 9,471 | $91.04 | $862,230.37 | -11.3% | |
| May 5, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sale+OE | 2,500 | $100.34 | $250,852.50 | -2.8% | |
| Mar 16, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 2,238 | $91.96 | $205,806.48 | -2.9% | |
| Mar 6, 2017 | BMRN Biomarin Pharmaceutical Inc | EVP, General Counsel | Sell | 1,498 | $93.32 | $139,793.36 | -1.9% |